| Current Price | $1.62 | Mkt Cap | $71.9M |
|---|---|---|---|
| Open | $1.57 | P/E Ratio | -1.80 |
| Prev. Close | $1.62 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $1.55 - $1.66 | Volume | 1,475,606 |
| 52-Wk Range | $1.20 - $2.79 | Avg. Daily Vol. | 579,060 |
| Current Price | $1.62 | Mkt Cap | $71.9M |
|---|---|---|---|
| Open | $1.57 | P/E Ratio | -1.80 |
| Prev. Close | $1.62 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $1.55 - $1.66 | Volume | 1,475,606 |
| 52-Wk Range | $1.20 - $2.79 | Avg. Daily Vol. | 579,060 |
The best Bull and Bear pitches based on recency and number of recommendations.
This is a tiny company with a drug that actually seems to work. Buying into a company this small and this early in development is probably not sober investing, but taking a small flyer is maybe justifiable. Lots or red flags here, but a… More
These guys haven't made money in at least 4 years, are probably looking at 'going concern' issues in the next 4 unless they do substantial dilution. I only looked at financials - maybe they have a miracle drug ready in the pipeline, but I also see a… More
Read the most recent pitches from players about CRDF.
Recs
odocoileus
(< 20)
Submitted: 2/3/2020 8:42:05 PM :
Start Price:
$1.68
NASDAQ:CRDF Score:
-42.11
This is a tiny company with a drug that actually seems to work. Buying into a company this small and this early in development is probably not sober investing, but taking a small flyer is maybe justifiable. Lots or red flags here, but a first-in-class 3rd generation PLK inhibitor that deserves some attention.
Recs
JohnnyMac28
(54.77)
Submitted: 10/22/2019 10:55:07 AM :
Start Price:
$1.98
NASDAQ:CRDF Score:
-59.64
A crazy pharma flier
Recs
DavidLTalbot
(< 20)
Submitted: 6/12/2015 8:12:43 AM :
Start Price:
$80.94
NASDAQ:CRDF Score:
-199.93
Been in since $5.89, worked out very well so far. Still a deep speculation play based on positive results for cancer mutation monitoring at several of the top cancer specialty hospitals. The key questions are:
1) Commercialization of the cancer mutation monitoring products (they have a few different ones for different cancers) which so far have been proven more effective than biopsies (urine sample versus cutting patient open, big diff) If this works out, this alone could justify a 750m market cap
2) Potentially creating and commercializing broader use urine tests like HPV (in testing) and potentially general cancer screenings for some of the hardest to detect killer cancers like pancreatic or lung cancers. This is further a-field speculation but if this part of the thesis works out it could justify a vastly higher market cap.
Like any speculative biotech play, you're either in for 10x or going to zero so not for the faint of heart.
Find the members with the highest scoring picks in CRDF.
glenn12345 (99.72) Score: +311.86
The Score Leader is the player with the highest score across all their picks in CRDF.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| Eric2204 | 99.89 | 8/20/2012 |
|
5Y | $14.10 | -88.51% | +199.60% | +288.11 | 0 Comment | |
| GSLogan | 81.70 | 9/20/2013 |
|
1Y | $42.18 | -96.16% | +148.83% | +244.99 | 0 Comment | |
|
glenn12345 | 99.72 | 5/31/2017 |
|
5Y | $3.90 | -58.46% | +76.46% | +134.93 | 0 Comment |
| johnnyrocku | 99.78 | 6/18/2018 |
|
5Y | $5.10 | -68.23% | +54.39% | +122.62 | 0 Comment | |
|
|
OttoBismarck | 99.69 | 11/12/2018 |
|
5Y | $4.57 | -64.57% | +55.36% | +119.93 | 0 Comment |
| TheGreatSatan | 89.20 | 1/19/2022 |
|
5Y | $5.62 | -71.17% | -7.16% | +64.02 | 0 Comment | |
| IdahoInvestor | 99.75 | 8/6/2019 |
|
5Y | $1.67 | -2.99% | +48.77% | +51.76 | 0 Comment | |
| wsmoot8796 | 64.03 | 7/1/2022 |
|
1Y | $2.19 | -26.03% | +12.95% | +38.98 | 0 Comment | |
| ak1010 | 99.61 | 7/19/2023 |
|
5Y | $1.54 | +5.19% | -6.52% | +11.72 | 0 Comment | |
| jon5555 | < 20 | 12/1/2022 |
|
5Y | $1.50 | +8.00% | +4.24% | -3.76 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
